European biotech ecosystem takes aim at changing the funding narrative
“The science is brilliant in Europe, but the translation is what’s lacking,” said V-Bio Ventures managing partner Christina Takke on …
Post
-
-
Ex-ACIP panel warns of ‘critically weakened’ US immunisation programme
Sweeping changes made by US health secretary Robert F Kennedy, Jr (RFK Jr) at the Centers for Disease Control and …
-
Teva to collaborate with Fosun Pharma for TEV-56278
Teva Pharmaceutical has announced a collaboration with Shanghai Fosun Pharmaceutical (Fosun Pharma) to advance the global development of the anti-programmed …
-
NextCure and Simcere partner to develop SIM0505 for solid tumours
NextCure has entered a strategic partnership with Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group, to develop SIM0505, a new …
-
Supernus makes depression drug play with $795m Sage buyout
Fewer than five months after rejecting a takeover approach by Biogen, Sage Therapeutics has found a buyer in Supernus Pharmaceuticals. According …
-
FDA approves MSD’s Keytruda to treat head and neck cancer
MSD has received US Food and Drug Administration (FDA) approval for its anti-programmed death receptor-1 (PD-1) therapy, Keytruda (pembrolizumab), for …
-
EHA 2025: AstraZeneca’s surovatamig is potential next-gen BiTE for R/R B-ALL
At the 2025 Congress of the European Hematology Association (EHA 2025), held from 12 June 12 to 15 June in …
-
Sarepta and Roche halt DMD gene therapy’s use after second death
Serepta and global partner Roche have discontinued the commercial and clinical use of Duchenne muscular dystrophy (DMD) gene therapy Elevidys …
-
Ethris and Thermo Fisher partner on mRNA solutions
Ethris has entered a strategic partnership with Thermo Fisher Scientific to provide a completely integrated messenger ribonucleic acid (mRNA) solution …
-
EHA 2025: Regeneron’s Lynozyfic with Amgen’s Kyprolis combo emerges for R/R MM
At the 2025 Congress of the European Hematology Association (EHA 2025), held from 12 June to 15 June in Milan, …
-
NICE approves GSK’s belantamab mafodotin for blood cancer
The National Health Service (NHS) England is set to become the first health system globally to offer the "Trojan horse" …
-
AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal
AstraZeneca has joined the long list of big pharma companies enlisting the services of Chinese biotechs, signing a deal worth …
-
Myasthenia gravis market to reach $10.3bn across 7MM by 2034
The myasthenia gravis (MG) market across the seven major markets (7MM: France, Germany, Italy, Japan, Spain, the UK and the …
-
Bharat Biotech acquires licence for GSK’s Shigella vaccine development
GSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biotech for continued development and distribution in low and middle-income …
-
The long road to acceptance: The slow adoption of ion chromatography in the pharmaceutical industry
Introduction Ion chromatography (IC), a highly sensitive technique for separating and quantifying ionic species, was introduced in the 1970s and marketed …
